Calibrated Methods for Quantitative PET/CT Imaging Phase II

定量 PET/CT 成像第二阶段的校准方法

• 批准号: 8979242
• 负责人: Andinet Asmamaw Enquobahrie
• 金额: $ 74.04万
• 依托单位: KITWARE, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8979242
• 关键词: Accounting; Algorithms; Automobile Driving; Biological Markers; Calibration; Characteristics; Clinical Trials; Comparative Study; Computer software; Data; Detection; Development; Geometry; Goals; Human; Image; Image Analysis; Imaging Device; Institutes; Letters; Location; Marketing; Measurement; Measures; Methods; Modeling; Molecular; Multi-Institutional Clinical Trial; Online Systems; PET/CT scan; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Positioning Attribute; Positron-Emission Tomography; Process; Property; Protocols documentation; Radioactive; Research Contracts; Resolution; Scanning; Services; Signal Transduction; Site; Slice; Small Business Technology Transfer Research; Source; Technology; Testing; Therapeutic Agents; Thick; Time; Translating; Universities; Variant; Washington; Work; X-Ray Computed Tomography; attenuation; base; cancer therapy; clinical practice; commercialization; cost; design; imaging modality; improved; oncology; public health relevance; reconstruction; response; tool

 DESCRIPTION (provided by applicant): The overall goal of this Phase II STTR proposal is to develop a PET/CT imaging tool that will help accelerate the development of effective cancer therapies by improving the utility of oncology trials using PET imaging. The growing cost, time, and complexity of clinical trials are driving patient and pharmaceutical company demand for more objective, efficient, and accurate methods to assess the efficacy of therapeutic agents. PET/CT imaging has the potential to provide a quantitative and early assessment of drug response at a molecular level However, PET/CT use as a biomarker and response endpoint in clinical trials is limited. Key factors impeding the incorporation of PET into clinical trials are:the considerable variability in imaging methods across centers, the inconsistency in quantitative measures arising from different sites, and the variable and non-optimal methods for image analysis. In our Phase I work, we developed calibrated quantitative analysis tools that directly support improved quantitative accuracy in clinical trials using PET/CT imaging. We combined the CT 'pocket phantom', developed by Kitware, with a PET scanner calibration process developed at the University of Washington (UW) that is based on National Institute of Standards and Technology (NIST) traceable calibration sources. We also extended our automated algorithms to detect and measure the phantom, and calculate key PET image characteristics. The Phase I proof-of concept study achieved its specific aims, and in this Phase II submission, we will develop and implement the studies and tools needed to translate our proof-of-concept results to use with human imaging for clinical trials. The end goal of the phase II project is to complete all necessary work to market PET/CT calibration and measurement phantoms and analysis services.

 描述（由申请人提供）：该 II 期 STTR 提案的总体目标是开发一种 PET/CT 成像工具，该工具将通过提高使用 PET 成像的肿瘤学试验的实用性来帮助加速有效癌症疗法的开发。临床试验的成本、时间和复杂性不断增加，促使患者和制药公司需要更客观、高效和准确的方法来评估治疗药物的疗效。 PET/CT 成像有潜力在分子水平上提供药物反应的定量和早期评估。然而，PET/CT 在临床试验中作为生物标志物和反应终点的用途是有限的。阻碍PET纳入临床试验的关键因素是：各中心的成像方法存在相当大的差异，不同地点的定量测量不一致，以及图像分析方法的可变性和非最佳性。在我们的第一阶段工作中，我们开发了校准的定量分析工具，可以直接支持使用 PET/CT 成像提高临床试验的定量准确性。我们将 Kitware 开发的 CT“袖珍体模”与华盛顿大学 (UW) 开发的 PET 扫描仪校准流程相结合，该流程基于美国国家标准与技术研究院 (NIST) 可追溯的校准源。我们还扩展了自动化算法来检测和测量体模，并计算关键 PET 图像特征。第一阶段概念验证研究实现了其特定目标，在第二阶段提交中，我们将开发和实施将我们的概念验证结果转化为用于临床试验的人体成像所需的研究和工具。第二阶段项目的最终目标是完成将 PET/CT 校准和测量体模及分析服务推向市场所需的所有工作。